These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27390032)

  • 1. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence.
    Kaiserman K; Jung H; Benabbad I; Karges B; Polak M; Rosilio M
    Pediatr Diabetes; 2017 Mar; 18(2):81-94. PubMed ID: 27390032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus.
    Kaiserman K; Rodriguez H; Stephenson A; Wolka L; Fahrbach JL
    Endocr Pract; 2012; 18(3):418-24. PubMed ID: 22297055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
    Reynolds NA; Wagstaff AJ
    Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
    Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
    Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
    Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
    Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.
    Garg S; Ampudia-Blasco FJ; Pfohl M
    Endocr Pract; 2010; 16(3):486-505. PubMed ID: 20150026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data.
    Ceriello A; Cremasco F; Romoli E; Rossi A; Gentilella R
    Expert Opin Pharmacother; 2012 Feb; 13(2):255-81. PubMed ID: 22242803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin pump therapy and rapid acting insulin: what have we learned?
    Zinman B
    Int J Clin Pract Suppl; 2001 Sep; (123):47-50. PubMed ID: 11594299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Insulin Lispro Protamine Suspension in Pregnancy.
    Lapolla A; Dalfrà MG; Romoli E; Bonomo M; Moghetti P
    Adv Ther; 2015 Oct; 32(10):888-905. PubMed ID: 26499176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars and Novel Insulins.
    Ampudia-Blasco FJ
    Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.
    Miles HL; Acerini CL
    Paediatr Drugs; 2008; 10(3):163-76. PubMed ID: 18454569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.